echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Courier can treat Alzheimer's disease by putting a "plaster" every week, and the innovative medication method is expected to be approved next spring

    Courier can treat Alzheimer's disease by putting a "plaster" every week, and the innovative medication method is expected to be approved next spring

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎ WuXi AppTec content team editor On October 12, 2021, Corium announced that the US FDA has set the new drug application (NDA) PDUFA target date for its donepezil (donepezil) transdermal patch Adlarity as March 11, 2022.
    For the treatment of patients with dementia caused by mild/moderate/severe Alzheimer's disease
    .

    According to statistics from the World Health Organization, more than 55 million people worldwide suffer from dementia, and Alzheimer's disease accounts for approximately 60%-70% of these patients
    .

    Alzheimer's disease is a progressive and irreversible neurodegenerative disease, and currently there is no cure
    .

    It can cause changes in brain tissue, including abnormal accumulation of protein and loss of neuronal function, resulting in loss of memory, reasoning and thinking ability
    .

    Donepezil is a common cholinesterase inhibitor (cholinesterase inhibitors)
    .

    The US FDA previously approved donepezil as a once-daily oral tablet for the treatment of patients with mild/moderate/severe Alzheimer's disease
    .

    Image source: 123RFAdlarity is a transdermal preparation of donepezil, made using Corium's proprietary Corplex technology platform
    .

    Adlarity transdermal patches can be applied continuously for 7 days and have consistent adhesion
    .

    This method of administration avoids the inconvenience caused by daily oral administration for patients with obvious memory problems
    .

    With the slow and stable release of donepezil, the Adlarity transdermal system can regularly deliver the drug through the skin.
    This design also avoids gastrointestinal absorption and related side effects
    .

    Corium is seeking to approve two Adlarity doses for transdermal delivery, each delivering 5 or 10 mg of donepezil daily
    .

    "Corium uses our innovative Corplex technology to improve the most commonly used first-line treatment for Alzheimer's disease patients," said Mr.
    Perry J.
    Sternberg, President and CEO of Corium.
    "Our team at Corium is committed to developing innovative drugs.
    To address the unmet treatment needs of people affected by Alzheimer’s disease and other central nervous system (CNS) diseases
    .

    "Reference: [1] Corium Receives March 11, 2022 PDUFA Date for New Drug Application for Adlarity® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease.
    Retrieved October 12, 2021, from https:// new-drug-application-for-Adlarity-patch-donepezil-transdermal-system-for-treatment-of-patients-with-alzheimers-disease-301397264.
    htmlDisclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research Progress
    .

    This article is for the purpose of information exchange only.
    The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
    .

    This article is not a treatment recommendation either
    .

    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.